Stock TLX TELIX PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Market Closed - Australian S.E.
Other stock markets
 02:10:52 2024-06-03 am EDT 		5-day change 1st Jan Change
18.25 AUD +0.55% Intraday chart for Telix Pharmaceuticals Limited +14.85% +81.05%
07:23am Jarden Research Adjusts Telix Pharmaceuticals’ Price Target to AU$16.62 From AU$13.94, Keeps at Buy MT
04:49am Telix Pharmaceuticals Completes US FDA Regulatory Submission for Kidney Cancer Imaging Agent MT

Evolution of the average Target Price on Telix Pharmaceuticals Limited

Price target over the last 5 years

History of analyst recommendation changes

3c46ad74c651c0.jXE730A5PsbPRUeCLT_s3Zh-p7gubzOzYNeMf_FPhY8.20Z4rAIMBrWWcQzSXW7UhKsz3dF3WmvkFuX6Fa4h6uD0RG6xNWsHqqImHg~ac1981f10f90f65a1f1854e3e7271d0c

Analyst Recommendations on Telix Pharmaceuticals Limited

Jarden Research Adjusts Telix Pharmaceuticals’ Price Target to AU$16.62 From AU$13.94, Keeps at Buy MT
Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50 MT
Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
18.15 AUD
Average target price
18.12 AUD
Spread / Average Target
-0.18%
High Price Target
26 AUD
Spread / Highest target
+43.25%
Low Price Target
13.9 AUD
Spread / Lowest Target
-23.42%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Telix Pharmaceuticals Limited

Bell Potter
Jarden Research

Ratings for Telix Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TLX Stock
  4. Consensus Telix Pharmaceuticals Limited